ABSTRACT

The relevance of prophylaxis of venous thromboembolism and its complications in orthopedic surgery is increasingly significant. This review discusses the pathophysiology of thrombus formation in general and orthopedic surgery, its incidence, predisposing factors and complications. It also presents an updated presentation and critique of prophylaxis currently available in our environment.

Keywords – Venous Thrombosis/prevention & control; Embolism/prevention & control; Orthopedics

INTRODUCTION

Prophylaxis of venous thromboembolism (VTE) and pulmonary embolism (PE) in orthopedic surgery, particularly in arthroplasties, continues to stir up considerable debate among health professionals, not only in Brazil, but worldwide.

This reality is part of an increasing awareness of two aspects: on one hand is the need to prevent avoidable complications with catastrophic repercussions, as can be the case with VTE and PE, and on the other, care to minimize the possible risks of bleeding associated with surgical procedures.

Studies in 1992 to compare enoxaparin and placebo in arthroplasties inform us that in the group submitted to prophylaxis, the presence of DVT detected by phlebography was 17%, while in the placebo group, it was 53% (p < 0.0001). On the other hand, the incidence of more severe bleeding occurred in 6% of the placebo group, and in 8% of the enoxaparin group, without statistical significance (p = 0.71)(1).

In fact, thromboembolic phenomena represent the more common complications in arthroplasties, including complications in the arteries(2) and, in particular, in the veins, which are the greatest cause of death in the first three months after surgery, representing more than 50% of postoperative mortality(3).

This condition leads to a growing level of demand that is incorporated into preventative care in major orthopedic surgeries in the United States(4) and at the same time, in the large medical centers.

Thrombosis can occur as part of the natural physiological process. In normal situations, there is a balance between factors that hinder and those that promote clotting. An alteration to this balance can lead to untimely clotting. On the other hand, clotting failures can lead to hemorrhage.

The Virchow’s triad

More than 150 years ago, Rudolf Virchow apud Merli(5) described the triad of factors responsible for thrombogenesis. These include: venous stasis, endothelial damage, and hypercoagulation. As can be seen, these three factors are closely linked to orthopedic procedures, particularly major ones, like arthroplasties.
The clotting cascade

The clotting mechanism consists of self-regulating processes that result in the production of a fibrin thrombus. These processes are controlled by inactive cofactors that, when activated, promote or accelerate clotting. These processes usually occur on the surfaces of the platelets or macrophages, or in the endothelial cells, and are initiated by two specific pathways: extrinsic and intrinsic.

The extrinsic pathway is initiated as a result of activation of tissue lipoproteins resulting from mechanical injuries such as trauma and/or surgery.

The intrinsic pathway involves circulating plasma factors.

Both pathways are found at the level of factor X, transformed into factor Xa. This factor promotes the conversion of prothrombin into thrombin (factor II), which, in turn, transforms the fibrinogen into fibrin, this being the key step for the formation of the thrombus.

The plasmin digests the fibrin, as well as inactivating the V and VIII factors and fibrinogen, restoring normal blood flow.

There are three anticlotting mechanisms that prevent the formation of thrombi: antithrombin III (ATIII), C and S proteins, and the extrinsic pathway inhibition (tissue factor).

When surgery and/or trauma occur, there is a decrease in circulating ATIII, instigating the clotting process. Studies have shown that this decrease in ATIII is greater, and remains for longer in total hip arthroplasties (THA) than in cases of general surgery. In patients with DVT diagnosed after surgery, the ATIII levels were low(6).

Localization of the thrombi

The majority of thrombi may develop in the deep veins of the calf, rising from here to the thigh; however, in up to 30% of clots, the primary origin may be higher up, in the iliofemoral venous segment, independent of any thrombi originating in the calf veins.

In terms of relationship with the operated limb, 80% of thromboses originate here, while in up to 20% of cases, they may originate in the healthy limb.

Most clots in the calf are small, and clinically insignificant. Likewise, proximal vein thrombosis may not be occlusive and asymptomatic, and in some cases, it regresses spontaneously, without any adverse effects. Meanwhile, there is an important link between proximal deep vein thrombosis and pulmonary embolism, and also between silent, non-occlusive thrombi and symptomatic or fatal pulmonary embolism(7,8).

The risks of venous thromboembolism in hospitalized patients

The risk of development of DVT in hospitalized patients is notably high, ranging from 10 to 20% in patients with clinical disorders and 80% or more in patients with spinal cord injury, or critical patients(9).

Among hospitalized patients and those submitted to surgery, patients who have undergone surgery for cancer, or orthopedic surgery, are at higher risk (Table 1).

Table 1 – Absolute risk of DVT in hospitalized patients.

<table>
<thead>
<tr>
<th>Group of patients</th>
<th>Prevalence (%) DVT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical patients</td>
<td>10–20</td>
</tr>
<tr>
<td>General surgery</td>
<td>15-40</td>
</tr>
<tr>
<td>Major gynecological surgery</td>
<td>15-40</td>
</tr>
<tr>
<td>Major urological surgery</td>
<td>15-40</td>
</tr>
<tr>
<td>Neurosurgery</td>
<td>15-40</td>
</tr>
<tr>
<td>Stroke</td>
<td>20-50</td>
</tr>
<tr>
<td>Arthroplasties of the hip or knee</td>
<td>40-60</td>
</tr>
<tr>
<td>Spinal cord injury</td>
<td>60-80</td>
</tr>
<tr>
<td>Major trauma</td>
<td>40-80</td>
</tr>
<tr>
<td>Critical patients</td>
<td>10-80</td>
</tr>
</tbody>
</table>

Rates based on DVT in patients not receiving thromboprophylaxis.

Venous thromboembolism and orthopedic surgery

The nature of orthopedic disorders and diseases, such as trauma, arthroplasties, particularly of the hip and knee, create a higher risk for the occurrence of venous thromboembolism.

The positioning of the limb during surgery, localized postoperative edema, and limitations in mobility immediately after surgery, all play a role in venous stasis and the consequent reduction of blood flow(10).

During surgery, manipulation of the limb, heat reaction resulting from the use of cement, and other aggressions can also activate thrombogenic factors that will manifest tropism for areas of vascular lesion and stasis(11). On the other hand, blood loss can reduce the antithrombin III levels and inhibit the endogenous fibrinolytic system, enabling the formation and growth of thrombi(12,13), at all levels.
During their evolution, many asymptomatic thrombi regress spontaneously without treatment, without extending this thrombus or evolving to PE or post-thrombotic syndrome (PTS)(14). Only one in eight thrombi identified by the venography will evolve to symptomatic DVT(15), while proximal thrombi (above the popliteal vein) have a higher likelihood of being symptomatic. However, around 10% of deaths occurring after THA are related to PE. It is known that between 3% and 4% of all symptomatic cases of VTE evolve to fatal PE(16).

Compared with other disorders that lead to hospitalization of patients, the rate of DVT among high-risk orthopedic patients is substantially higher, including in patients hospitalized for clinical complaints or even other surgeries. A study by Geerts et al(17) showed that patients who did not use prophylaxis and were submitted to THA had a rate of DVT of 50-60%, of which 20-30% were proximal. The total incidence was even higher in patients after TKA, with a rate of 60-85% of total DVT, but with a lower rate of proximal DVT of 9-20%. Patients with hip fractures had a total rate of DVT of 30-60%, of which up to 36% were proximal. In these same series, the risk of fatal PE was 0.4-12.9% (Table 2).

Another important data is presented to us by Falck-Ytter et al(18), who, in their work, give graphs comparing the cumulative evolution of VTE in the first 90 days postoperative, comparing non-prophylaxis with the use of LMWH.

From a temporal perspective, studies located the peak risk of DVT and PE at around the third and fourth weeks postoperative, for hospitalized patients(19) (Figure 1).

Other cohort studies suggest that the peak manifestation of DVT occurs around the first month, and can remain up to the 12th week(20).

An analysis of 11,607 patients submitted to total hip arthroplasty (THA) between 1976 and 1985 showed a relative risk of 2.85 for the occurrence of DVT and PTE as the cause of death in the first three months postoperative, when compared with the remainder of the year(21).

When primary arthroplasties of the hip and knee were studied, the DVTs appeared to be more prevalent in the first group(22) (Figure 2).

### Pulmonary thromboembolism (PTE)

Pulmonary thromboembolism may be the most feared complication of VTE. Its presentation is varied, and can range from fulminant conditions to mild dyspnea, or even a total absence of symptoms. The rate of lethality accompanies this heterogeneity, ranging from more than 60% to less than 1% of cases(23).

Diagnosis is often difficult due to the variable symptoms, and the use of algorithms may be useful(24) (Figure 3).

Once the diagnosis has been made, treatment should begin immediately, and should clearly follow distinct parameters from those used for prophylaxis,

### Table 2 – Risk of VTE after orthopedic surgery in patients who did not receive prophylaxis.

<table>
<thead>
<tr>
<th>Surgery</th>
<th>Total DVT</th>
<th>Proximal DVT</th>
<th>Total PTE</th>
<th>Fatal PTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>TKA</td>
<td>41-85</td>
<td>05-22</td>
<td>1.5-10</td>
<td>0.1-1.7</td>
</tr>
<tr>
<td>THA</td>
<td>42-57</td>
<td>18-36</td>
<td>0.9-28</td>
<td>0.1-2.0</td>
</tr>
<tr>
<td>Hip fracture</td>
<td>46-60</td>
<td>23-30</td>
<td>03-11</td>
<td>0.3-7.5</td>
</tr>
</tbody>
</table>

with an initial phase of five days, which may extend to three months, or in cases of high risk of relapse, for the remainder of the patient’s life(24) (Figure 4).

**Prophylaxis**

Based on all the above mentioned characteristics, it is clear that prophylaxis of DVT is necessary in orthopedic procedures, and particularly, though not exclusively in arthroplasties.

Within this perspective, tools for raising awareness among professionals to follow the guidelines can play an important role(26).

Orthopedic surgeons have generally demonstrated good awareness in the use of thromboprophylaxis, compared with professionals of other medical specialties. In 2008, a questionnaire to members of the American Association of Hip & Knee Surgeons (AAHKS) showed that the majority of those questioned (> 80%) agreed with the preoperative assessment protocols of risk factors for VTE, and with postoperative prophylaxis (pharmacological and mechanical). Furthermore, 28% reported that they had changed their prophylactic practice in the last five years, in accordance with the ACCP and/or AAOS(27).

A recent questionnaire of the American Association of Hip and Knee Surgeons indicated that 100% of their members used some method of prophylaxis for DVT. In 2003, the result (HIP and KNEE Registry) showed that one or more types of prophylaxis were carried out in 99% of patients. Approximately 89% of THA patients and 91% of TKA patients received prophylaxis according to the recommendations of the 7th ACCP(20).

In our context, in hospitals of São Paulo, a study involving 1454 patients (589 surgical and 865 clinical) showed that despite the existence of various guidelines, thromboprophylaxis is not carried out appropriately: high-risk patients are undertreated, and low-risk patients are overtreated(28).

This circumstance needs to be changed to ensure patients receive adequate treatment for the prevention of thromboembolism.

**VTE risk assessment**

A simplified risk assessment can be useful in the initial clinical assessment of the patient.

The Diretrizes (Guidelines) project, carried out in partnership with the Brazilian Medical Association and the Federal Council of Medicine, gives a clear picture of the risk assessment of DVT, and possible measures to be taken(29) (Figure 5).
MECHANICAL PROPHYLAXIS

Methods of prophylaxis

Although the use of low-molecular-weight heparin (LMWH) or non-fractionated heparins (NFH) represent the most common model of prophylaxis in our context, other alternatives can be listed, and critically considered. Initially, we can divide prophylaxis into mechanical and pharmacological.

Mechanical methods

Methods such as graduated elastic compression stockings (GECS), intermittent pneumatic compression (IPC), and plantar venous pump (PVP) increase blood flow and reduce venous stasis. These methods have the benefit that they have no risk of bleeding, presenting advantages in patients with an increased risk of bleeding. On the other hand, these methods may be difficult to implement or maintain, due to the limited movement of the patient and the discomfort they can bring. They are also contraindicated in situations such as exposed fracture, infection of the lower limbs, peripheral arterial insufficiency, severe cardiac insufficiency, and ulceration of the lower limbs.

The start of prophylaxis with mechanical methods may be the method of choice in patients with a high risk of bleeding; however, when this risk is temporary, prophylaxis should be initiated, by pharmacological means, as soon as the risk decreases. Another factor to be considered is irregular use of these methods, and training in their correct use, and they should only be discontinued for very short periods (during walking or when using the bathroom).

Current data (9th ACCP) suggest the use of mechanical methods in addition to pharmacological prophylaxis during hospitalization, in patients with a high risk for DVT in major orthopedic surgeries(18).

Pharmacological prophylaxis

Until a few years ago, heparin and warfarin were, in practice, the only drugs used in anticoagulant therapy. They are widely available, cheap, effective, and contain specific antidotes. However, they are considered problematic due to the need for their careful monitoring.

Warfarin has a slow onset of action, interacts with various drugs and foods, has a narrow therapeutic window, and has initial paradoxal prothrombic action.

Heparin requires monitoring when used for therapeutic purposes, and is associated with the development of thrombosis and bleeding, a condition known as heparin-induced thrombocytopenia (HIT).

Platelet antiaggregants: acetylsalicylic acid (ASA) and clopidogrel

Acetylsalicylic acid and clopidogrel are medications with permanent and temporary platelet aggregation inhibiting action, respectively.
The use of ASA as a prophylactic agent for VTE is controversial. Although ASA is more effective than placebo in the prophylaxis of VTE the 9th ACCP does not recommend its use as the sole prophylactic method in orthopedic surgeries, due to the lack of definitive evidence of its action, and the possibility of gastric alterations\(^{(18)}\).

While platelet antiaggregants are of little use in the prevention of venous thrombosis, they are essential in the prevention of arterial thrombosis, and can represent a risk in orthopedic procedures.

In fact, the need to deal with patients using ASA and clopidogrel in the prevention of coronary obstruction, and the use of pharmacological stents, may represent a challenge for the orthopedic team, since in these cases, suspending the medication can pose a risk of thrombosis of the stent. In this condition, the risks of suspending clopidogrel should be weighed against the risk of increased bleeding that is generated by double antiplatelet therapy\(^{(32)}\).

If the risk of bleeding is too high, the suspended antiplatelet therapy should be resumed as soon after surgery as is reasonably possible.

**Warfarin**

Warfarin, through vitamin K blockade, is an inhibitor of gamma-carboxylation of various blood clotting factors (factors II, VII, IX, X, and proteins C and S). It does not act on the circulating clotting factors, only on their synthesis in the liver, which explains its delayed effect.

Although widely used in North America, here in Brazil, warfarin is little used as prophylaxis in orthopedic surgery, mainly due to its therapeutic variability, wide drug interactions, food interactions, and the need for laboratory monitoring.

When used, warfarin depends on the control of prothrombin activity through the measurement of the INR (International Normalized Ratio).

As an undesirable effect, warfarin presents, from the onset, a slight procoagulant effect, which may require concomitant use of heparin in the first 72 hours.

**Tecarfarin**

Tecarfarin is a recent oral anticoagulant, of the vitamin K epoxide-reductase family of antagonists. Unlike warfarin, it is metabolized by esterases, and not by the cytochrome P450 system, thereby avoiding drug interactions. On the other hand, it appears to be more stable to control by the INR than warfarin. It is currently in phase III clinical trials, and is not yet available here in Brazil\(^{(33)}\).

**Non-fractionated heparin (NFH)**

Heparin is an activator of the blood enzyme antithrombin III. This enzyme inhibits various coagulation factors (II, IX, and X) and more significantly, thrombin, which forms the fibrin thrombus. Non-fractionated heparin (NFH) is used in low doses by the subcutaneous (SC) route, which may be 10,000ui SC every 12 hours, or 5,000ui SC every 8 hours. One of the most feared adverse effects is heparin-induced thrombocytopenia (HIT), in which there is formation of anti-heparin antibodies/platelet factor, plateletopenia, with prothrombotic effect, which can develop bleeding, thrombosis and embolisms, and even death. When there is suspicion of HIT, heparin should be suspended immediately.

**Low-molecular-weight heparin (LMWH)**

This is obtained through the depolymerization of heparin and acts, mainly, blocking the factor Xa. It can be used subcutaneously, generally in a single daily application, without requiring laboratory monitoring. This means it can be applied safely and effectively in the patient’s home. Currently, the most commonly used drugs in Brazil are:

- enoxaparin in the presentations of 20 mg (used in patients with creatinine clearance > 30 ml/min) or 40 mg, the dosage more commonly used as prophylaxis in orthopedic surgeries; and
- dalteparin in the 2,500 UI and 5,000 UI presentations.

Despite the possibility of developing HIT, various studies suggest that the incidence of HIT during prophylaxis with LMWH is lower when compared with NFH. Due to its safety and efficiency, enoxaparin is used today as gold standard for the development of new anticoagulant drugs.

**Fondaparinux**

Fondaparinux is a pentasaccharide, whose antithrombotic activity is the result of selective inhibition of the factor Xa mediated by antithrombin III (ATIII). The neutralization of factor Xa interrupts the blood clotting cascade, thereby inhibiting the formation of thrombin and the development of the thrombus.

As a benefit over other injectable presentations, it does not inactivate thrombin (activated factor II), it has no effect on the platelets, and it does not cross-react with the serum of patients with heparin-induced thrombocytopenia.

A total of 144,806 patients were included in a study that showed a lower incidence of VTE with fondaparinux (1.5%), compared with enoxaparin (2.3%), dalteparin...
(2.1%) and NFH (4.2%). Significantly fewer patients in
the fondaparinux group had some episode or were read-
mitted to hospital due to an episode of VTE, compared
with those taking other medications(34).

In patients with lowered renal function, particularly el-
derly diabetic patients and those with a high risk of bleeding,
the dose of LMWH or fondaparinux should be reduced.

New anticoagulant drugs

a) rivaroxaban

Rivaroxaban is a highly selective, direct inhibitor of
factor Xa, and is available by oral administration. The
inhibition of factor Xa interrupts the intrinsic and ex-
trinsic pathways of the clotting cascade, inhibiting the
formation and development of thrombin. Rivaroxaban
does not inhibit thrombin (activated factor II) and has
no effect on the platelets(35).

More than 9,500 patients (7,050 in THA and 2,531 in
TKA) were evaluated in randomized, phase III, double-
blind clinical trials known as the RECORD-programme.
The dose used was rivaroxaban 10 mg, initiated up to 6
hours of closure of the surgical wound, compared with
enoxaparin 40 mg SC, initiated 12 hours before surgery.

Total DVT occurred in 79 out of 824 patients (9.6%)
who received rivaroxaban and in 166 out of 878 (18.9%)
who received enoxaparin (absolute risk reduction, 9.2%);
proximal DVT occurred in nine out of 908 patients
(1.0%) with rivaroxaban and in 24 out of 925 (2.6%)
with enoxaparin (absolute risk reduction, 1.6%). Sym-
tomatic events occurred less frequently with rivaroxaban
than with enoxaparin (p = 0.005). Major bleeding in
0.6% of the patients of the rivaroxaban group and 0.5%
of the patients of the enoxaparin group. The incidence of
adverse effects, the majority gastrointestinal, was 12.0%
with rivaroxaban and 13.0% with enoxaparin.

b) dabigatran

Dabigatran etexilate is a direct oral inhibitor of
thrombin. Its efficacy was analyzed in studies that
compare dabigatran etexilate (220 or 150 mg per day)
with enoxaparin. The first study(36) involved a total
of 2101 patients submitted to TKA (150 mg or 220
mg once daily) and the second(37) involved a total of
3494 patients submitted to THA. In both studies, the
main parameter of efficacy was the number of VTE
or deaths by any cause during the treatment period.

In both studies, dabigatran etexilate was as effec-
tive as enoxaparin in preventing VTE or death.

Recently, however, studies have reported a relation-
ship between the use of dabigatran and an increase
of coronary events, including myocardial infarction(38),
which places its use in doubt, pending further studies.

Current prophylaxis proposals

The ninth edition (2012) of the evidence-based
clinical guidelines of the American College of Chest
Physicians(18) contains guidelines for prevention in
major orthopedic surgery, namely:

Elective arthroplasty of the hip or knee

Extended use after discharge up to the 35th day after
surgery of one of the following: LMWH and alternative-
ly, fondaparinux, apixaban, rivaroxaban, NFH, Vitamin K antagonist, Aspirin® (polemic).

*During hospitalization: intermittent pneumatic compression (more
than 18 hours/day).

Hip fracture

Extended use after discharge up to the 35th day after
surgery of one of the following: LMWH, and alternative-
ly, fondaparinux, NFH, Vitamin K antagonist, Aspirin®
(polemic).

*During hospitalization: intermittent pneumatic compression (more
than 18 hours/day).

Extended prophylaxis

In a study from 1998, 19,586 THA and 24,059 TKA
with cumulative incidence of VTE, the mean time to diag-
nosis was 2.8% and 2.1, respectively; after surgery, it was
17 days for THA and seven days for TKA. Although 88%
of these patients received prophylaxis while hospitalized,
76% and 74% of the thromboembolic events were diagno-
sed after discharge from hospital, and only 32% of these
patients continued with the prophylaxis at home(8).

A multicenter trial with 15,020 patients showed
that those who received LMWH continued throughout
every phase of the trial, i.e. even after discharge.
However, approximately 37% of patients submitted to
THA who initially received LMWH, did not continue
to receive it after discharge, which is currently
a recommendation of the ACCP Guidelines. By
contrast, the duration of prophylaxis with warfarin
with or without IPC was shorter(9).

Currently, the recommendation is to maintain pro-
phylaxis for VTE in patients submitted to THA and in
the postoperative phase of fracture of the femur for at
least four weeks, and in patients submitted to TKA, for
at least ten days. Patients who have suffered spinal cord trauma, with total lesion of the spinal cord should receive anticoagulation medication for at least six weeks.

**Anesthetic blockade**

Systematic reviews have demonstrated that neuraxial blockade reduced cardiac and pulmonary morbidity and bleeding when compared with general anesthesia. Pain control and patient satisfaction are also improved with this method. Meanwhile, in patients using anticoagulant medications, a rare, but more devastating complication can occur: epidural or spinal cord hematoma (19).

Some care should be taken to increase the safety of the anesthetic blockade in patients receiving or who will receive anticoagulants. For example: contraindicating anesthetic blockade in patients with clotting alterations.

Anti-inflammatories and ASA do not appear to increase the risk of subdural or spinal cord hematoma.

Clopidogrel should be suspended for at least seven days prior to the blockade.

**INDICATION**

**Total knee arthroplasty (TKA)**

For patients submitted to TKA, the following should be used:

- enoxaparin 40 mg SC 1x daily, initiating up to 12 hours pre- or postoperative. Or if the above is not possible:
  - dalteparin 5.000ui SC 1x daily, initiating up to 12 hours postoperative.
  - dabigatran 110 mg, oral route, initiated 1 to 4 hours postoperative, 24h after the first dose, two 110 mg tablets together.
  - rivaroxaban 10 mg, oral route, 1x daily, initiated 6 to 12 hours postoperative.
  - Vitamin K blockers.

Prophylaxis should be used for at least 10 to 14 days, possibly extending to 35 days, depending on the associated risk factors.

**Total hip arthroplasty (THA)**

According to the 2012 Guidelines of the 9th ACCP, prophylaxis with LMWH is recommended for at least four weeks, using the following:

- enoxaparin 40 mg SC 1x daily, initiating up to 12 hours pre- or postoperative. Or if the above is not possible:
  - dalteparin 5.000ui SC 1x daily, initiating up to 12 hours postoperative.
  - dabigatran 110 mg, oral route, initiated 1 to 4 hours postoperative, 24h after the first dose, two 110 mg tablets together.
  - rivaroxaban 10 mg, oral route, 1x daily, initiated 6 to 12 hours postoperative.
  - vitamin K blockers.

Graduated elastic compression stockings may be used (20-30 mmHg in the ankle) throughout this period, in association with the pharmacological methods, decreasing still further the risk of VTE, as well as improving the edema, facilitating walking.

Prophylaxis should be used for at least 10 to 14 days, possibly extending to 35 days, depending on the associated risk factors.

**Knee arthroscopy**

In less aggressive surgeries, such as knee arthroscopy, the phenomenon of VTE can also be seen in studies using doppler US and venography in patients who have not received prophylaxis. These data suggest an incidence of 9.9% for total DVT and 2.1% for proximal DVT (35), which makes the analysis of the risk of VTE and eventual prophylaxis interesting in these patients too. In young patients with no other risk factor for VTE, the only option should be early walking. No other method is indicated for prophylaxis in DVT.

For patients with some risk factor for VTE, or a complicated procedure, prophylaxis should be discussed, whether mechanical or pharmacological, which may be continued in the patient’s home for up to seven days (39).

**FINAL CONSIDERATIONS**

Thromboprophylaxis may represent one of the greatest benefits to be offered to a patient who requires – whether by choice or emergency – an orthopedic intervention, particularly arthroplasties of the lower limbs.

In an open analysis study of VTE in three years of
follow-up at a university hospital with 3300 surgeries and 15,000 patients treated annually, the incidence of VTE in the classical high-risk groups in hip fracture, THA and TKA were low, with approximately 0.6%, and that of pulmonary embolism of 0.27%, with two cases of death by pulmonary embolism, occurring on days 72 and 109 after surgery. Patients with hip fractures had more VTE. The majority of cases of VTE occurred after discharge.

These data show us the importance of prophylaxis and its potential in the reduction of risks in orthopedic patients.

REFERENCES


2. Fidelis Júnior R, Amatuzzi MM; Leão PP; Leme LEG. Trombose arterial rela-


4. Sharrock NE, Go G, Harpel PC, Ranawat CS, Sculco TP, Salvati EA. Thrombo-


12. Eriksson BI, Eriksson E, Gyzander T, Teger-Nilsson AC, Risberg B. Thrombo-

13. Francis CW, Ricotta JJ, Evarts CM, Marder VJ. Long-term clinical observations and its potential in the reduction of risks in ortho-


28. Hoening H, Rubenstein LV, Sloane R, Horner K, Kahn K. What is the role of ti-


30. Baviotomo LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM, Tercatarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy parti-

31. Hoenig H, Rubenstein LV, Sloane R, Horner R, Kahn K. What is the role of ti-


